Total Clarity Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Total Clarity Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-42	Closed	-$4K	–	824
2021 Q4	$4K	Hold	42	–	–	﹤0.01%	849
2021 Q3	$4K	Buy	+42	New	+$3.23K	﹤0.01%	861
2021 Q2	–	Sell	-42	Closed	-$3K	–	670
2021 Q1	$3K	Buy	+42	New	+$3.88K	﹤0.01%	762
2020 Q1	–	Sell	-42	Closed	-$5K	–	549
2019 Q4	$5K	Buy	+42	New	+$4.24K	﹤0.01%	592

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Total Clarity Wealth Management's SRPT Position: Q1 2022 in Review

Total Clarity Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 42 shares — an estimated $4K sold.

Total Clarity Wealth Management first reported a position in SRPT in Q4 2019 and held it in 4 quarters. The position peaked at $5K in Q4 2019. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

Total Clarity Wealth Management reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
Total Clarity Wealth Management sold 42 Sarepta Therapeutics shares in Q1 2022, an estimated $4K.
Total Clarity Wealth Management first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 4 quarters.
Total Clarity Wealth Management's Sarepta Therapeutics position peaked at $5K in Q4 2019.
328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Total Clarity Wealth Management's 13F filing for Q1 2022, filed 29 Apr 2022.